BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30691310)

  • 1. Enhancement of the effect of BCG vaccine against tuberculosis using DDA/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV.
    Mansury D; Ghazvini K; Amel Jamehdar S; Badiee A; Tafaghodi M; Nikpoor AR; Amini Y; Jaafari MR
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):370-377. PubMed ID: 30691310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing Cellular Immune Response in Liposomal Formulations of DOTAP Encapsulated by Fusion Protein Hspx, PPE44, And Esxv, as a Potential Tuberculosis Vaccine Candidate.
    Mansury D; Ghazvini K; Amel Jamehdar S; Badiee A; Tafaghodi M; Nikpoor AR; Amini Y; Jaafari MR
    Rep Biochem Mol Biol; 2019 Jan; 7(2):156-166. PubMed ID: 30805395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
    Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
    Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chitosan nanoparticles containing fusion protein (Hspx-PPE44-EsxV) and resiquimod adjuvant (HPERC) as a novel booster vaccine for
    Hoseinpur R; Hasani A; Baradaran B; Abdolalizadeh J; Amini Y; Salehi R; Samadi Kafil H; Azizian K; Memar MY; Gholizadeh P; Hasani A
    J Biomater Appl; 2022 Jul; 37(1):40-47. PubMed ID: 35430919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.
    Qu W; Li N; Yu R; Zuo W; Fu T; Fei W; Hou Y; Liu Y; Yang J
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):852-860. PubMed ID: 29447484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
    Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
    Front Immunol; 2020; 11():575504. PubMed ID: 33117374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system.
    McNeil SE; Rosenkrands I; Agger EM; Andersen P; Perrie Y
    J Pharm Sci; 2011 May; 100(5):1856-65. PubMed ID: 21374619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying.
    Christensen D; Foged C; Rosenkrands I; Nielsen HM; Andersen P; Agger EM
    Biochim Biophys Acta; 2007 Sep; 1768(9):2120-9. PubMed ID: 17555704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen.
    Henriksen-Lacey M; Bramwell VW; Christensen D; Agger EM; Andersen P; Perrie Y
    J Control Release; 2010 Mar; 142(2):180-6. PubMed ID: 19874860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
    Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
    Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of trehalose 6,6'-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes.
    Kallerup RS; Madsen CM; Schiøth ML; Franzyk H; Rose F; Christensen D; Korsholm KS; Foged C
    Eur J Pharm Biopharm; 2015 Feb; 90():80-9. PubMed ID: 25445301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlating liposomal adjuvant characteristics to in-vivo cell-mediated immunity using a novel Mycobacterium tuberculosis fusion protein: a multivariate analysis study.
    Kastner E; Hussain MJ; Bramwell VW; Christensen D; Perrie Y
    J Pharm Pharmacol; 2015 Mar; 67(3):450-63. PubMed ID: 25677402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses.
    Kaur R; Bramwell VW; Kirby DJ; Perrie Y
    J Control Release; 2012 Feb; 158(1):72-7. PubMed ID: 22032883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice.
    Soleimanpour S; Farsiani H; Mosavat A; Ghazvini K; Eydgahi MR; Sankian M; Sadeghian H; Meshkat Z; Rezaee SA
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10467-80. PubMed ID: 26373723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
    Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
    J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.
    Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y
    Mol Pharm; 2011 Feb; 8(1):153-61. PubMed ID: 21117621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
    Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
    J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against
    Tian M; Zhou Z; Tan S; Fan X; Li L; Ullah N
    Front Immunol; 2018; 9():310. PubMed ID: 29535714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvants Based on Synthetic Mycobacterial Cord Factor Analogues: Biophysical Properties of Neat Glycolipids and Nanoself-Assemblies with DDA.
    Kallerup RS; Franzyk H; Schiøth ML; Justesen S; Martin-Bertelsen B; Rose F; Madsen CM; Christensen D; Korsholm KS; Yaghmur A; Foged C
    Mol Pharm; 2017 Jul; 14(7):2294-2306. PubMed ID: 28497975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.